癌症生物模拟纳米传递系统的最新进展 免疫疗法 免疫疗法
Jiawei Yang1, Xueqi Li1, Tongyu Li2
1Cixi Biomedical Research Institute, Wenzhou Medical University, Zhejiang, China, No. 508 North Second Ring East Road, Ningbo, 315302, Zhejiang, China.
Materials today. Bio
|April 24, 2025
概括
生物模拟纳米递送系统 (BNDS) 通过增强药物递送和免疫逃避,为瘤免疫疗法提供了一种有前途的方法. 这些系统显示出克服当前癌症治疗方法的局限性的潜力.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 纳米技术纳米技术
- 生物材料是一种生物材料.
背景情况:
- 瘤免疫疗法显示出有希望的结果,但由于复杂的瘤免疫微环境和患者的变异性,它面临着局限性.
- 向瘤环境和免疫系统是有效的癌症治疗的关键策略.
研究的目的:
- 审查生物模拟纳米输送系统 (BNDS) 在瘤免疫治疗中的作用.
- 探索瘤免疫微环境与免疫疗法疗效之间的关系.
- 讨论用于BNDS的细胞膜的工程及其应用.
主要方法:
- 关于瘤免疫学和纳米输送系统的综合文献综述.
- 对生物仿真应用的细胞膜工程技术的分析.
- 在癌症免疫治疗中对不同类型的基于膜的BNDS进行分类和评估.
主要成果:
- 使用细胞膜和纳米颗粒的BNDS具有高准效率,药物递送能力和免疫逃逸特性.
- 这些系统整合了天然细胞膜和纳米颗粒的优势,以改善瘤向.
结论:
- 在瘤免疫疗法中,BNDS代表了显著的进步,提供了更高的疗效,克服了当前的治疗挑战.
- 对基于膜的BNDS的前景和挑战进行进一步的研究对于其临床转化至关重要.
相关概念视频
Tumor Immunotherapy
398
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
398
Cancer Vaccines
238
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
238


